Baseline hepatitis B surface antigen (HBsAg) positivity is a significant protective factor for reactivation of hepatitis B virus (rHBV) in patients with HBsAg-negative, HBV core antibody (HBcAg)-positive rheumatoid arthritis (RA) receiving rituximab (RTX) therapy, according to study results published in the International Journal of Rheumatic Diseases.1
Worldwide, approximately 2 billion people are infected by HBV, and 75% of them inhabit Southeast Asia and the Western Pacific regions.2,3 A considerable number of patients with RA have coexisting HBV infection, and RA is a risk factor for developing rHBV as a result of using immunosuppressive therapies.4-7 RTX is used for treating patients with RA with an inadequate response to anti-tumor necrosis factor (TNF)-alpha therapy, and rHBV has recently been recognized as a complication of RTX therapy.8-18
Therefore, researchers in Taiwan examined the occurrence of rHBV in 157 patients with RA who were receiving RTX therapy.1 They found that of these patients, 103 (65.6%) were HBsAg-negative and HBcAb-positive. However, before RTX therapy, 20 (19.4%) of these 103 patients were HBsAg-negative, while 83 (80.1%) were HBsAb-positive. Of the patients who tested HBsAb-negative, 5 (20%) developed rHBV after RTX therapy and of the 83 patients who tested HBsAb-positive, 4 (4.8%) developed rHBV. Of the 9 patients with rHBV, 7 (77.7%) exhibited HBsAg seroconversion. Overall, a significant decline of HBsAg titers was observed in patients who were HBsAg-negative/HBsAb-positive, and HBsAb positivity was found to be an independent protective factor for rHBV (P =.009).
“In conclusion, our results showed that RTX therapy can induce rHBV in the early phase for HBsAg‐positive patients and in the late phase for those with resolved HBV infection,” stated the investigators.1They added that, “Future prospective studies are needed to investigate the optimal frequency of HBV‐DNA monitoring, and the optimal duration of antiviral therapy in RA patients receiving RTX therapy.”
By Virginia Schad
1. Chen Y‐M, Chen H‐H, Huang W‐N, et al. Reactivation of hepatitis B virus infection following rituximab treatment in HBsAg‐negative, HBcAb‐positive rheumatoid arthritis patients: A long‐term, real‐world observation [published online May 22, 2019]. Int J Rheum Dis. doi:10.1111/1756-185X.13582
2. Dienstag JL. Hepatitis B virus infection. N Engl J Med. 2008;359:1486‐1500.
3. Sung JL, Chen DS, Lai MY, et al. Hepatitis B e antigen and antibody in asymptomatic Chinese with hepatitis B surface antigenemia in Taiwan. Gastroenterol Jpn. 1982;17:341-346.
4. Calabrese LH, Zein NN, Vassilopoulos D. Hepatitis B virus (HBV) reactivation with immunosuppressive therapy in rheumatic diseases: assessment and preventive strategies. Ann Rheum Dis. 2006;65:983‐989.
5. Lan JL, Chen YM, Hsieh TY, et al. Kinetics of viral loads and risk of hepatitis B virus reactivation in hepatitis B core antibody‐positive rheumatoid arthritis patients undergoing anti‐tumor necrosis factor alpha therapy. Ann Rheum Dis. 2011;70:1719‐1725.
6. Chen MH, Chen MH, Liu CY, et al. Hepatitis B virus reactivation in rheumatoid arthritis patients undergoing biologics treatment. J Infect Dis. 2017;215:566‐573.
7. Fukuda W, Hanyu T, Katayama M, et al. Incidence of hepatitis B reactivation in patients with resolved infection on immunosuppressive therapy for rheumatic disease: a multicenter, prospective, observational study in Japan. Ann Rheum Dis. 2017;76:1051-1056.
8. Boye J, Elter T, Engert A. An overview of the current clinical use of anti‐CD20 monoclonal antibody rituximab. Ann Oncol. 2003;14:520‐535.
9. Cohen SB, Emery P, Greenwald MW, et al. for the REFLEX trial group. Rituximab for rheumatoid arthritis refractory to anti‐tumor necrosis factor therapy: results of a multicenter, randomized, double‐blind, placebo‐controlled, phase III trial evaluating primary efficacy and safety at twenty‐four weeks. Arthritis Rheum. 2006;54:2793‐2806.
10. Yeo W, Chan TC, Leung N, et al. Hepatitis B virus reactivation in lymphoma patients with prior resolved hepatitis B undergoing anticancer therapy with or without rituximab. J Clin Oncol. 2009;27:605‐611.
11. Mitroulis I, Hatzara C, Kandili A, Hadziyannis E, Vassilopoulos D. Long‐term safety of rituximab in patients with rheumatic diseases and chronic or resolved hepatitis B virus infection. Ann Rheum Dis. 2013;72:308‐310.
12. Pyrpasopoulou A, Douma S, Vassiliadis T, Chatzimichailidou S, Triantafyllou A, Aslanidis S. Reactivation of chronic hepatitis B virus infection following rituximab administration for rheumatoid arthritis. Rheumatol Int. 2011;31:403‐404.
14. Gigi E, Georgiou T, Mougiou D, et al. Hepatitis B reactivation in a patient with rheumatoid arthritis with antibodies to hepatitis B surface antigen treated with rituximab. Hippokratia. 2013;17:91‐93.
15. Droz N, Gilardin L, Cacoub P, et al. Kinetic profiles and management of hepatitis B virus reactivation in patients with immune‐mediated inflammatory diseases. Arthritis Care Res. 2013;65:1504‐1514.
16. Paul S, Dickstein A, Saxena A, et al. Role of surface antibody in hepatitis B reactivation in patients with resolved infection and hematologic malignancy: a meta‐analysis. Hepatology. 2017;66:379‐388.
17. Hsiao L‐T, Chiou T‐J, Gau J‐P, et al. Risk of reverse seroconversion of hepatitis B virus surface antigen in rituximab‐treated non‐Hodgkin lymphoma patients: a large cohort retrospective study. Medicine. 2015;94:e1321.
18. Tien YC, Yen HH, Chiu YM. Incidence and clinical characteristics of hepatitis B virus reactivation in HBsAg‐negative/HBcAb‐positive patients receiving rituximab for rheumatoid arthritis. Clin Exp Rheumatol. 2017;35:831‐836.